Novo Nordisk
NVO

Novo Nordisk (NVO) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
BMO CapitalMaintainedMarket Perform$40.00 from $47.00Oct 12, 2026
Morgan StanleyDowngradedEqual-Weight → Underweight$40.00Sep 11, 2026
Goldman SachsDowngradedBuy → Neutral$41.00 from $63.00Mar 2, 2026
JP MorganDowngradedOverweight → Neutral—Feb 24, 2026
CICCInitiated CoverageOutperform$73.50Jan 9, 2026
Argus ResearchDowngradedBuy → Hold—Dec 8, 2025
Goldman SachsMaintainedBuy$54.00 from $60.00Nov 28, 2025
BMO CapitalMaintainedMarket Perform$46.00 from $50.00Nov 25, 2025
HSBCDowngradedBuy → Hold—Nov 24, 2025
JefferiesInitiated CoverageUnderperform—Oct 27, 2025
BMO CapitalMaintainedMarket Perform$55.00 from $50.00Oct 14, 2025
HSBCUpgradedHold → Buy$70.00Oct 2, 2025
Morgan StanleyDowngradedEqual-Weight → Underweight$47.00 from $59.00Sep 29, 2025
BerenbergUpgradedHold → Buy—Sep 17, 2025
TD CowenMaintainedBuy$70.00 from $105.00Aug 19, 2025
UBSDowngradedBuy → Neutral—Aug 5, 2025
HSBCDowngradedBuy → Hold—Jul 31, 2025
BarclaysDowngradedOverweight → Equal-Weight—Jul 30, 2025
BMO CapitalDowngradedOutperform → Market Perform$64.00 from $105.00Apr 17, 2025
UBSUpgradedSell → Buy—Jan 8, 2025

Frequently asked questions

  • What is the latest analyst rating on NVO?

    On Oct 12, 2026, BMO Capital maintained Novo Nordisk at Market Perform with a price target of $40.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.